CompoAtlas

BIOBAY REZWEL CAPSULE

BIOBAY REZWEL CAPSULE : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Registration number
MAL24086064TC
Type
Natural product
Published status
PRODUCT APPROVED
Licence holder
GALAXIS HEALTHCARE SDN BHD
Manufacturer
BELIVE HEALTHCARE SDN. BHD.
Registration period starting
2024-08-01
Published validity end
2029-08-01

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
Apocynum venetumApocynum venetum[25 mg,460 mg]Not identified
Humulus lupulusHumulus lupulus[100 mg,460 mg]Not identified
Lycium barbarumLycium barbarum[100 mg,460 mg]Not identified
Passiflora incarnataPassiflora incarnata[75 mg,460 mg]Not identified
Valeriana officinalisValeriana officinalis[100 mg,460 mg]Not identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Original register data

View published fields and their variants
Active ingredients
Apocynum venetum[25 mg,460 mg],Humulus lupulus[100 mg,460 mg],Lycium barbarum[100 mg,460 mg],Passiflora incarnata[75 mg,460 mg],Valeriana officinalis[100 mg,460 mg]
Valid until
2029-08-01
Registration date
2024-08-01
Published description
NATURAL PRODUCT
Licence holder
GALAXIS HEALTHCARE SDN BHD
Producer
BELIVE HEALTHCARE SDN. BHD.
Published name
BIOBAY REZWEL CAPSULE
Published reference
2024020514003T
Registration number
MAL24086064TC
Published status
PRODUCT APPROVED

Official source

View the official register, number MAL24086064TC

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Humulus lupulus
    Read the warning, when it applies and the studies cited

    HOPS - HUMULUS LUPULUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Other uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; McGuffin et al. 1997).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as this product may cause drowsiness (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 26 April 2024

  • Passiflora incarnata
    Read the warning, when it applies and the studies cited

    PASSIONFLOWER -PASSIFLORA INCARNATA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • Valeriana officinalis
    Read the warning, when it applies and the studies cited

    Valerian - VALERIANA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 July 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line